|Last Price$3.33||Day Change (%)-2.35%|
|Open Price$3.42||Day Change ($)-0.08|
|Day Range3.30–3.47||52-Week Range3.05–13.26|
As of Wed 10/22/2014 03:59 PM EST | USD
Cytokinetics' CYTK ispinesib trial results for head and neck cancer did not yield a statistically significant change in its patients. We are leaving our fair value estimate at $3.50 per share, as we had already assigned a low probability of success for this indication. Our more conservative ...
Cytokinetics faces challenging odds.